Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by Institut Paoli-Calmettes
Information provided by (Responsible Party):
Institut Paoli-Calmettes Identifier:
First received: October 30, 2013
Last updated: December 31, 2013
Last verified: December 2013

Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation

Condition Intervention
Ovarian Cancer
Endometrium Cancer
Cervix Cancer
Other: gynecological cancer

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010

Resource links provided by NLM:

Further study details as provided by Institut Paoli-Calmettes:

Primary Outcome Measures:
  • molecular alteration in gynecological cancer [ Time Frame: average of 4 weeks after diagnosis ] [ Designated as safety issue: No ]
    gene expression level

Secondary Outcome Measures:
  • relation between molecular alteration and clinical and histological characteristics [ Time Frame: up to 10 years ] [ Designated as safety issue: No ]
    hazard ratio between molecular alteration and clinico-histological characteristics

Estimated Enrollment: 300
Study Start Date: December 2013
Estimated Study Completion Date: December 2028
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: gynecological cancer
blood and tumor samples
Other: gynecological cancer
blood and tumor samples


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • gynecological cancer
  • age > 18
  • signed informed consent

Exclusion Criteria:

- emergency

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01977274

Contact: Agnès BOYER CHAMMARD 33491223778

Institut Paoli Calmettes Recruiting
Marseille, France, 13 009
Contact: Agnes BOYER CHAMMARD, MD         
Principal Investigator: Eric LAMBAUDIE, MD         
Sponsors and Collaborators
Institut Paoli-Calmettes
  More Information

Additional Information:
No publications provided

Responsible Party: Institut Paoli-Calmettes Identifier: NCT01977274     History of Changes
Other Study ID Numbers: GC-BIO-IPC 2013-010
Study First Received: October 30, 2013
Last Updated: December 31, 2013
Health Authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé

Keywords provided by Institut Paoli-Calmettes:
ovarian, endometrium, cervix cancer

Additional relevant MeSH terms:
Ovarian Neoplasms
Uterine Cervical Neoplasms
Adnexal Diseases
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Site
Ovarian Diseases
Urogenital Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Uterine Neoplasms processed this record on November 27, 2014